BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
BioMarin and n-Lorem will carry out preclinical studies and jointly select a lead candidate for trials.
Drug Development
Argenx signs agreement to buy Forte Biosciences for $2.2bn
Biointron introduces RushData platform for AI-driven antibody discovery
Kenvue’s Tylenol with Naproxen gains FDA approval
BeOne to invest $300m in US manufacturing facility expansion
FDA grants fast track designation for Lundbeck’s Lu AH69593
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Evogene and ELEO to develop new oral PCSK9 inhibitors
